(Total Views: 700)
Posted On: 09/27/2022 7:40:50 AM
Post# of 148892
Re: Buddyboy20 #128705
Good article.
It mentions mitochondrial dysfunction as a possible contributing factor to Alzheimer's. Leronlimab has that taken care of,
https://investorshangout.com/post/view?id=6231450
The main thrust of the article is that Alzheimer's is an autoimmune disease. The overactive immune response that leads to inflammation and autoimmunity also leads to mitochondrial dysfunction.
If you're targeting very specific things like most drugs do you're going to miss wide swathes of other contributing factors. For instance if you have a drug that targets only CCL3 you may help reduce immune response a bit, but you'll be missing CCL5, mTORc1, TFN-y, NF-kB and a host of other factors that will still contribute to an overactive immune response. By targeting CCR5 a main controller of the immune response leronlimab can take care of a wide variety of those factors.
It mentions mitochondrial dysfunction as a possible contributing factor to Alzheimer's. Leronlimab has that taken care of,
https://investorshangout.com/post/view?id=6231450
The main thrust of the article is that Alzheimer's is an autoimmune disease. The overactive immune response that leads to inflammation and autoimmunity also leads to mitochondrial dysfunction.
If you're targeting very specific things like most drugs do you're going to miss wide swathes of other contributing factors. For instance if you have a drug that targets only CCL3 you may help reduce immune response a bit, but you'll be missing CCL5, mTORc1, TFN-y, NF-kB and a host of other factors that will still contribute to an overactive immune response. By targeting CCR5 a main controller of the immune response leronlimab can take care of a wide variety of those factors.
(19)
(0)Scroll down for more posts ▼
